853 results about "Dry eyes" patented technology

The invention relates to recombinant III-type humanized collagen and application of a composition containing the same to eyes. The invention provides an application of recombinant III type humanized collagen in preparation of a product for preventing and / or treating eye inflammation, a composition containing the recombinant III type humanized collagen, and an application of the composition in preparation of a product for preventing and / or treating eye inflammation and / or eye dryness. The recombinant III-type humanized collagen and the composition containing the recombinant III-type humanized collagen can obviously promote updating and repairing of corneal epithelial cells, and meanwhile, can inhibit release of inflammatory mediators, enhance eye tissue barriers, enhance tear film stability and relieve eye inflammation and eye dryness.

The invention relates to the technical field of artificial intelligence, and discloses a traditional Chinese medicine diabetes dry eye treatment difference evaluation system and method based on artificial intelligence, and the system comprises a four-diagnosis integrated module, a syndrome modeling module, an intelligent decision module, a curative effect feedback module, a knowledge base management module and a self-adaptive learning module. Multi-mode traditional Chinese medicine four-diagnosis data of tongue condition, pulse condition and eye diagnosis and modern physiological parameters of metabolic indexes are fused, a deep learning method is adopted for standardization processing, the problem that traditional Chinese medicine syndrome differentiation depends on subjective experience is solved, traditional Chinese medicine syndrome feature extraction of diabetes dry eye has objectivity and quantifiability, and the traditional Chinese medicine syndrome feature extraction efficiency is improved. The comprehensiveness and the accuracy of the diagnosis basis are improved; and the curative effect feedback module compares a prediction result with revival curative effect data in real time, and the knowledge base management module is linked to carry out case feature matching and strategy optimization, so that continuous optimization and long-term reliability of the treatment decision model are ensured.

The purpose of the present invention is to provide a novel therapeutic agent or prophylactic agent for dry eye, a therapeutic agent or prophylactic agent for a graft-versus-host disease, a corneal epithelial wound healing promoter, an inflammatory cell inhibitor that infiltrates the cornea, a tear fluid amount retaining agent, a corneal epithelial disorder inhibitor, a cell proliferation marker-positive cell inhibitor, and an inhibitor of lymphocyte differentiation into effector T cells. The present invention provides the following, each of which contains, as an active ingredient, a substance derived from a culture supernatant of stem cells: a therapeutic agent or prophylactic agent for dry eye; a therapeutic agent or prophylactic agent for a graft-versus-host disease; a corneal epithelial wound healing promoter; an inflammatory cell inhibitor infiltrating into the cornea; a tear fluid amount retaining agent; a corneal epithelial disorder inhibitor; a cell proliferation marker-positive cell inhibitor; or an inhibitor of lymphocyte differentiation into effector T cells.

The purpose of the present invention is to provide: a novel therapeutic or prophylactic agent for xerophthalmia; a therapeutic or prophylactic agent for graft-versus-host disease; a corneal epithelium wound healing promoter; a corneal invasive inflammatory cell inhibitor; or an inhibitor of differentiation of lymphocytes into effector T cells. The present invention provides: a therapeutic or prophylactic agent for xerophthalmia, a therapeutic or prophylactic agent for graft-versus-host disease, a corneal epithelial wound healing promoter, a corneal invasive inflammatory cell inhibitor, a tear amount maintenance agent, a corneal epithelial damage inhibitor, and a method for preparing the same, which comprises, as an active ingredient, a substance derived from a stem cell culture supernatant; a cell proliferation marker positive cell inhibitor, or an inhibitor of differentiation of lymphocytes to effector T cells.

A dry eye composition containing hypochlorous acid and a demulcent. The demulcent can be polyvinylpyrrolidoe with a molecular weight of 30-50 kDa. The composition can be applied to the surface of the eye with a dropper device or a spray dispenser. Critically, hypochlorous acid is stable in the dry eye composition and maintains its effectiveness at preventing microbial growth.

The present disclosure provides compounds and pharmaceutically acceptable salts thereof for inhibiting CYP26B1. Aspects of the present disclosure also include methods of using the compounds to treat diseases or disorders, including, but not limited to, skin disorders, cancer, neurological disorders, heterotopic ossification (HO), fibrodysplasia ossificans progressiva (FOP), multiple osteochondromas, and diseases or disorders of the eye, including meibomian gland dysfunction and dry eye disease.

The utility model relates to the technical field of contact lenses, and particularly discloses a comfortable sclera lens which comprises an outer surface, the inner side of the outer surface is connected with an optical area, the periphery of the optical area is sequentially provided with a first transition area, a second transition area and a landing area, the first transition area and the second transition area are connected with each other, and the optical area is not in contact with the cornea. A plurality of liquid guide grooves are evenly formed in the inner side of the landing area at intervals, the inner ends of the liquid guide grooves penetrate through the first transition area and the second transition area and extend to the edge of the optical area, through holes are formed in the positions, close to the edge of the landing area, of the bottoms of the liquid guide grooves, and the through holes penetrate through the landing area. According to the sclera lens, the plurality of liquid guide grooves are formed, tear exchange between the sclera lens and the periphery of the eyes can be achieved after the sclera lens is worn, the situation that the eyes are dry after the sclera lens is worn for a long time is relieved, meanwhile, the through holes are formed in the inner sides of the liquid guide grooves, the tear exchange efficiency can be further improved through the through holes, the oxygen permeation rate can be improved, and the comfort degree is high when the sclera lens is worn.

The invention relates generally to the field of medical devices and, more specifically, to a handheld device that stimulates the meibomian gland of the eyelid mechanically, and specifically stimulates the meibomian glands of the eyelid to treat Meibomian gland dysfunction, also known as “Dry eye” and chronic marginal eyelid inflammation.

The invention discloses an image processing system and method for distinguishing xerophthalmia types, and relates to the technical field of image processing, and the method comprises the steps: firstly carrying out the standardization preprocessing of an original infrared meibomian gland image, further introducing an artifact perception link, and actively recognizing and positioning the interference regions, such as eyelash shielding and uneven illumination, in the image; and guiding the subsequent meibomian gland segmentation process by using the sensed artifact information, thereby realizing the accurate extraction of the meibomian gland form under the complex background. On the basis, multi-dimensional quantification is carried out on the precisely segmented gland form, and image features are converted into objective numerical indexes. And finally, carrying out comprehensive judgment on the numerical indexes by utilizing a decision tree model, and outputting standardized MGD severity grade. In this way, interference information brought by image artifacts can be intelligently suppressed, and therefore more robust and accurate MGD severity grading is achieved in a clinical image with poor quality.

The invention relates to the field of biological medicine, in particular to a carrier-free nanoparticle which is formed by self-assembly of cyclosporine A and costunolide through intermolecular weak interaction. The invention also provides a preparation method of the traditional Chinese medicine composition and application of the traditional Chinese medicine composition in preparation of medicines for treating xerophthalmia. The carrier-free nano eye drops based on the synergistic effect of Chinese and western medicines are used for anti-inflammatory treatment of the xerophthalmia, a new strategy is provided for precise diagnosis and treatment of the xerophthalmia, the problems of single target spot, limited curative effect and the like in traditional treatment are solved, and more efficient inflammation control is expected to be achieved. While the curative effect is improved, the tolerance risk caused by long-term use is reduced, double optimization of the curative effect and safety is realized, and the limitation of traditional single drug treatment is broken through. By adopting the carrier-free nano preparation, the delivery efficiency of the medicine on the ocular surface is effectively improved, the bioavailability is enhanced, powerful support is provided for improving the curative effect of the medicine, and the carrier limitation bottleneck is broken through.

The invention discloses a dry eye disease course supervision and prediction method and system based on AI image recognition, and relates to the technical field of medical image processing, and the method comprises the steps: obtaining blink behavior video data, meibomian gland infrared imaging data and time sequence ocular surface microvessel image data; analyzing the blink behavior video data, and extracting blink feature data; performing image processing on the infrared imaging data of the meibomian glands, and extracting feature data of the meibomian glands; carrying out binarization and thinning processing on the sequential ocular surface microvascular image data, and extracting blood vessel feature data; standardizing the blood vessel feature data, and fusing to generate a comprehensive feature vector; inputting the comprehensive feature vector into a classification model, and judging a dry eye disease course stage; executing trend analysis based on historical data of the comprehensive feature vector, and generating prediction data and intervention suggestion data; the method has the beneficial effects that through multi-modal image data fusion analysis, accurate monitoring and prediction of the xerophthalmia course are realized, and a scientific basis is provided for clinical intervention.

The invention provides a traditional Chinese medicine composition for treating dry eyes as well as a preparation method and application thereof, and belongs to the technical field of traditional Chinese medicine compositions. The preparation method of the traditional Chinese medicine composition comprises the following steps: taking 3-12 parts by weight of tripterygium wilfordii and 3-12 parts by weight of mint as raw material medicines, mixing, adding water, decocting, carrying out solid-liquid separation, and concentrating the filtrate to obtain the traditional Chinese medicine composition. According to the invention, tripterygium wilfordii is taken as a main medicine and is matched with mint with the effect of dispelling wind and heat to jointly form the eye fumigating prescription capable of dispelling wind and clearing heat, and the eye fumigating prescription comprises active ingredients such as triptolide, tripterine and the like, and can regulate and control inflammatory response of ocular surface; local administration is carried out by adopting an ultrasonic atomization method, so that liver and kidney injury caused by liver and kidney metabolism of oral medicines can be avoided, most of active ingredients only play roles in eyes and do not enter blood circulation, the toxicity of tripterygium wilfordii is reduced, only anti-inflammatory and immunosuppression efficacy of tripterygium wilfordii is taken, local administration directly reaches a disease site, and the treatment effect on dry eyes is definite.

The present disclosure relates to methods of treating chronic conditions of the eye, such as dry eye disease and blepharitis, as well as to methods for increasing secretion of meibum. This disclosure also relates to formulations suitable for treating chronic conditions of the eye such as dry eye disease and blepharitis.

The present invention relates generally to compositions, formulations, and methods for immunotherapy and drug delivery, including the treatment of eye diseases such as dry eye disease (DED). In particular, the present invention relates to methods of producing exosomes from mesenchymal stem cells (MSC-Exos) and, optionally, loading said exosomes with one or more bioactive substances. The exosomes may be loaded using electroporation with one or more bioactive substances such as proteins, miRNAs, and / or siRNA. In specific embodiments, the exosomes, and / or one or more biological compounds derived from the exosomes, may be provided to an individual in need thereof, including as part of one or more compositions containing mesenchymal stem cells (MSCs). The individual in need thereof may be an individual having a medical disorder such as DED, immune disorders, cancer, and other disorders. Therefore, the compositions containing MSCs can be used for topical application to the eye. The compositions can contain MSCs, MSC-Exos, one or more MSC-derived biological compounds (e.g., growth factors, proteins, etc.).

The present invention provides formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile (compound I) and methods for treating ocular surface pain by administering such formulations. The present invention also provides methods for treating dry eye disease and ocular hyperemia by administering formulations of 4-(7-hydroxy-2-isopropyl-4-oxo-4H-quinazolin-3-yl)-benzonitrile.

Described herein are methods and pharmaceutical formulations for treating dry eye disease.

The invention provides an eye drop composition as well as a preparation method and application thereof, and belongs to the technical field of ophthalmic preparations. The eye drop composition adopted by the invention is prepared from the following components: brimonidine tartrate, hyaluronic acid, collagen, trehalose and injection water. By compounding the components, the eye drops which can realize slow release of brimonidine tartrate and prolong the antihypertensive action time and have the characteristics of relieving blink discomfort, long-acting moisturizing, anti-inflammatory soothing, mildness, corrosion prevention and the like are prepared; the eye drops are beneficial to people suffering from glaucoma, intraocular hypertension, xerophthalmia, postoperative inflammation or allergy and preservative sensitivity or preservative allergy, the life quality is improved, and diseases are relieved.

In one aspect, a computerized method includes the step of obtaining a set of eye data of a patient from a medical practitioner in a computer input form. The method includes the step of acquiring a set of dry eye patient data from a set of well-structured dry eye patient data samples, wherein each sample dry eye patient data comprises a plurality of features. The method includes the step of identifying the plurality of data features in the set of well-structured dry eye patient data samples. The method includes the step of implementing a data cleaning process on the set of well-structured dry eye patient data samples. The method includes the step of implementing a feature selection on the set of well-structured dry eye patient data samples, wherein the feature selection comprises selecting a subset of relevant features for machine-learning model construction. The method includes the step of providing a specified machine-learning (ML) model. The method includes the step of training the ML model with the set of well-structured dry eye patient data samples. The method includes the step of validating the ML model with the set of well-structured dry eye patient data samples. The method includes the step of providing the set of eye data of the patient to the trained and validated ML model. With the trained and validated ML model, the method includes the step of classifying the set of eye data of the patient as a dry eye category and a dry eye type.

The invention provides a soft hydrophilic contact lens material, a soft hydrophilic contact lens as well as a preparation method and application of the soft hydrophilic contact lens. The soft hydrophilic contact lens material comprises the following components in percentage by weight: 70%-99% of a hydrophilic monomer, 0.1%-10% of an antioxidant monomer, 0.05%-6% of a cross-linking agent, 0.005%-5% of an initiator and 0.5%-15% of a diluent. According to the invention, the hydrophilic monomer and the antioxidant monomer are used, so that the material has high softness, the wearing comfort is improved, and the antioxidant monomer improves the oxidation resistance of the soft hydrophilic contact lens material and reduces free radicals in the wearing process of the contact lens, thereby reducing the possibility of inflammatory response and the possibility of dry eyes of the contact lens. Meanwhile, the antioxidant monomer has an ultraviolet absorption function and can bring a cell ultraviolet protection effect, and the hydrophilic monomer and the antioxidant monomer both have good biological safety, so that the safety of the material is improved.

According to the xerophthalmia core index multi-task AI detection system, method and terminal provided by the invention, the xerophthalmia multi-modal image is collected and exclusive preprocessing is completed, and core index detection is carried out on the preprocessed image based on the xerophthalmia multi-index detection model, so that the xerophthalmia core index detection result is obtained. Outputting detection results such as meibomian gland deletion rate, tear film rupture time, staining classification, tear river height and blepharitis marginal inflammation classification; and dynamically adjusting the index result according to a calibration coefficient corresponding to the type of the data acquisition equipment, and finally generating a standardized detection report. A xerophthalmia multi-index detection model is constructed based on an improved U-Net3 + architecture, a dry eye feature enhancement encoder and a cross-scale feature fusion decoder are adopted, a customized multi-task detection head is matched, an inter-task attention collaboration mechanism is established, meanwhile, a preprocessing algorithm and a dynamic calibration mechanism matched with a dry eye image are designed, and the detection accuracy of the xerophthalmia is improved. And multi-index synchronous, high-precision and high-efficiency detection is effectively realized.

A system for the treatment of the dry eye syndrome that is based on a light source. The system includes a disposable tip, to treat an eyelid. A corneal shield is used to protect the patient's eye.

The present invention relates to pharmaceutical composition comprising combination of Lifitegrast and Loteprednol etabonate along with one or more pharmaceutically acceptable excipients for the treatment of dry eye disease.

Disclosed herein are methods of using cyclosporine A ophthalmic gel in treating moderate to severe dry eye disease.

The invention provides pharmaceutical compositions comprising about 0.05 to 0.1% (w / v) cyclosporine dissolved in 1-perfluorobutyl-pentane for use in the topical treatment of dry eye disease and provides for dosing and treatment methods thereof. The invention further provides kits comprising such compositions.

The present invention discloses a traditional Chinese medicine composition for treating dry eye and a preparation method thereof. The traditional Chinese medicine composition for treating dry eye is made from the following components in parts by weight: 10-12 parts of Chinese wolfberry, 5-10 parts of chrysanthemum, 10-15 parts of cassia seed, 10-12 parts of cortex fraxini, 5-10 parts of safflower, and 10-12 parts of phellodendron amurense. The traditional Chinese medicine composition for treating dry eye prepared by this method has less dosage, is convenient to use, safe and without side effects when treating dry eye, and has a significant therapeutic effect in aspects such as prolonging the breakup of the tear film, increasing the tear flow rate, and improving corneal staining, and can be promoted as a drug for treating dry eye.

Dry eye treatment apparatus and methods are described herein which generally comprise a patch or strip affixed to the skin of the upper and / or lower eyelids to deliver heat or other forms of energy, pressure, drugs, moisture, etc. (alone or in combination) to the one or more meibomian glands contained within the underlying skin. The treatment strip or strips include one or more strips configured to adhere to an underlying region of skin in proximity to one or both eyes of a subject such that the one or more strips allow for the subject to blink naturally without restriction from the one or more patches. Moreover, the one or more strips may be configured to emit energy to the underlying region of skin and where the one or more strips are shaped to follow a location of one or more meibomiam glands contained within the underlying region of skin.

The invention features ALK2 antibodies and antigen binding fragments thereof (e.g., ALK2 binding fragments). The invention also features pharmaceutical compositions and methods of using the ALK2 antibodies or antigen binding fragments thereof to treat bone disease or damage, low red blood cell levels (e.g., anemia or blood loss), heterotopic ossification (e.g., heterotopic ossification resulting from fibrodysplasia ossificans progressiva), Sjogren's syndrome (e.g., dry eye associated with Sjogren's syndrome), multiple osteochondroma, diffuse intrinsic pontine glioma, posterior capsule opacification, or cardiac hypertrophy and / or cardiac fibrosis.

The invention belongs to the technical field of artificial intelligence, and discloses a dry eye diagnosis and treatment integrated system based on a deep neural network, which comprises an input unit module, a diagnosis unit module, a data matching module and an output unit module, and is characterized in that dry eye symptoms and OSDI scale result characteristics of a patient to be diagnosed are input through the input unit module; the diagnosis unit module obtains the dry eye symptom, the OSDI scale and the corresponding relation between the lower tear river height and the mild dryness, moderate dryness and severe dryness of a patient, the data matching module matches the result features of the dry eye symptom, the OSDI scale and the psychological survey scale of the patient to be diagnosed into the corresponding relation, and a corresponding matching diagnosis report is generated. And finally, outputting grading diagnosis of light, moderate and heavy dry eyes of the patient to be diagnosed through an output unit module. The system can help clinicians to improve the diagnosis efficiency of dry eye grading and reduce missed diagnosis and misdiagnosis, and is high in operability.

Described herein are methods of treating a disease, disorder or a condition associated with dry eye caused by a multifactorial disease of ocular surface, comprising administering to a subject in need thereof a pharmaceutical composition comprising a therapeutically effective amount of a modified FGF-1 polypeptide.